Incorporating Life-cycle Price Modelling into Pharmaceutical Cost-effectiveness Evaluations

Michele Pistollato

Grant-Funded Research from Office of Health Economics

Abstract: Why might the launch price of a new drug be a poor indicator of future expenditure for a drug? Which are the factors that determine the future prices and market shares of a drug? Understanding the answers to these questions can be crucial when conducting cost-effectiveness analyses i.e. when studying if it is desirable to publicly fund reimburse a new drug. This paper models and studies the price of a new drug along its life-cycle, from launch to discontinuation, to understand how the price of the drug evolves and to help inform cost-effectiveness evaluations.

Keywords: Incorporating; Life-cycle; Price; Modelling; into; Pharmaceutical; Cost-effectiveness; Evaluations (search for similar items in EconPapers)
JEL-codes: I1 (search for similar items in EconPapers)
Date: 2015-08-01
References: Add references at CitEc
Citations:

Downloads: (external link)
https://www.ohe.org/publications/incorporating-lif ... ffect-evaluations-2/ (application/pdf)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:ohe:grafun:001632

Access Statistics for this paper

More papers in Grant-Funded Research from Office of Health Economics Contact information at EDIRC.
Bibliographic data for series maintained by Publications Manager ( this e-mail address is bad, please contact ).